Journal of Clinical Pharmacology and Toxicology is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal of Clinical Pharmacology and Toxicology or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial.

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). At the time of writing on 7th of April 2020 the WHO indicates that 211 countries, areas or territories are affected, with around 70’000 deaths worldwide. It is evident that the scientific community must come together to mitigate the many clinical and public health management challenges.

The COVID-19 outbreak poses global pressure on modern societies and particularly healthcare related infrastructure. Nanotechnology brings new prospects for developing affordable and scalable detection methods, safe personal protection equipment and new effective medical solutions.

Nanosensors are already a reality, showing great ability to detect bacteria and viruses at very low concentrations and thus warn clinicians even before symptoms have shown or on patients with very low viral loads.

A nano-filter has been recently developed that is claimed to maintain filtering efficiency, even after hand washing, through the use of nanofibers. This reusable nano-filtered face mask could help to relieve the challenges arising from the supply shortage of face masks.

Researchers have been investigating the potential of using nanoparticles to treat bacterial and viral infections for years now. Gold nanoparticles, for example, are made to attach to viruses such as Ebola or influenza and by heating the particles with certain infrared wavelengths, the nanoparticles can then destroy the structure of the virus. Nanoparticles can be used to deliver drugs as well.

On the occasion of its 3 years, Successful Journey, Journal of Clinical Pharmacology and Toxicology decided to provide a partial waiver on its article processing charges to promote quality research from across the nations of the globe to encourage the latest research in the field of Infections, Diseases and Medicine. Journal of Clinical Pharmacology and Toxicology also planning to release a special issue on its new approaches.

Regards

Mary Wilson

Editorial office

Journal of Clinical Pharmacology and Toxicology

E-mail: pharmatoxicol@eclinicalsci.com